NCT01126112View on ClinicalTrials.gov

Study of First-line Single-agent Panitumumab in Frail Elderly Patients With Advanced Wild Type K-RAS Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

Panitumumab

Panitumumab: 6 mg/Kg Q2W

Trial Locations (1)

28046

Spanish Cooperative Group for Gastrointestinal Tumour Therapy, Madrid

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

OTHER